Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | CES1 | P23141 | 3/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277101 | 1.00 | ANPEP (0.77) | ANPEPTSHRTHRBLMNAALDH1A1 | |
| Pentadecylboronic Acid SCHEMBL2130881 | 1.00 | ANPEP (0.77) | ANPEPTSHRTHRBLMNAALDH1A1 | |
| SCHEMBL125433 | 1.00 | — | — | |
| SCHEMBL17492031 | 1.00 | ANPEP (0.77) | ANPEPTSHRTHRBLMNAALDH1A1 | |
| SCHEMBL6805211 | 1.00 | ANPEP (0.77) | ANPEPTSHRTHRBLMNAALDH1A1 | |
| SCHEMBL6917203 | 1.00 | ANPEP (0.77) | ANPEPTSHRTHRBLMNAALDH1A1 | |
| SCHEMBL2132055 | 1.00 | ANPEP (0.77) | ANPEPTSHRTHRBLMNAALDH1A1 | |
| SCHEMBL128905 | 1.00 | ANPEP (0.77) | ANPEPTSHRTHRBLMNAALDH1A1 | |
| SCHEMBL187268 | 1.00 | ANPEP (0.77) | ANPEPTSHRTHRBLMNAALDH1A1 | |
| SCHEMBL28476586 | 1.00 | ANPEP (0.77) | ANPEPTSHRTHRBLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114008497-B | Polarizing film and method for producing same | 株式会社可乐丽 | 2025-02-25 | — | — | CN | disclosed |
| CN-114096899-B | Polarizing film and method for producing same | 株式会社可乐丽 | 2025-01-03 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-115244440-A | Polarizing film and method for producing same | 株式会社可乐丽 | 2022-10-25 | — | — | CN | disclosed |
| CN-111615654-B | Polarizing film and method for producing same | 株式会社可乐丽 | 2022-06-17 | — | — | CN | disclosed |
| CN-114174875-A | Polarizing film and method for producing same | 株式会社可乐丽 | 2022-03-11 | — | — | CN | disclosed |
| CN-114096899-A | Polarizing film and method for producing same | 株式会社可乐丽 | 2022-02-25 | — | — | CN | disclosed |
| CN-114008497-A | Polarizing film and method for producing same | 株式会社可乐丽 | 2022-02-01 | — | — | CN | disclosed |
| CN-107709339-B | Antiviral and antibacterial preparations based on quaternary ammonium compounds complexed with boric acid and derivatives thereof | B-有机电影公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-111615654-A | Polarizing film and method for producing same | 株式会社可乐丽 | 2020-09-01 | — | — | CN | disclosed |
| EP-2182026-B1 | Method to improve cold flow resistance of polymers | BRIDGESTONE CORP (JP) | 2011-05-25 | — | — | EP | disclosed |
| EP-2182026-A1 | Method to improve cold flow resistance of polymers | Bridgestone Corporation (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20100036026-A1 | METHOD TO IMPROVE COLD FLOW RESISTANCE OF POLYMERS | BRIDGESTONE CORPORATION (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20090209492-A1 | Lipase Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209492-A1 | Lipase Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209492-A1 | Lipase Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2009-08-20 | — | — | US | disclosed |
| EP-1824861-A2 | LIPASE INHIBITORS | Trustees of the Tufts College (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20070140973-A1 | CONTRAST AGENTS FOR MYOCARDIUM PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2007-06-21 | — | — | US | disclosed |
| WO-2007070827-A2 | CONTRAST AGENTS FOR MYOCARDIUM PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2006053250-A2 | LIPASE INHIBITORS | TRUSTEES OF TUFTS COLLEGE (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209492-A1 | Lipase Inhibitors | LIPG, LPL, PNLIP | ANPEP 608/4885TSHR 3579/4885THRB 3102/4885 |
| US-20070140973-A1 | CONTRAST AGENTS FOR MYOCARDIUM PERFUSION IMAGING | TNNI3, TNNT2, TNNC1 | ANPEP 1570/4885TSHR 2938/4885THRB 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.